Published in J Control Release on April 10, 2010
HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol (2012) 1.55
Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta (2010) 1.50
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1.08
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev (2011) 1.00
Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol (2013) 0.99
ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss. Autophagy (2014) 0.98
HER2 therapies and gastric cancer: a step forward. World J Gastroenterol (2013) 0.96
Radiation-guided drug delivery to mouse models of lung cancer. Clin Cancer Res (2010) 0.95
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm (2011) 0.92
Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles. Int J Nanomedicine (2012) 0.90
Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data. Bioinformatics (2014) 0.90
Bioengineering strategies for designing targeted cancer therapies. Adv Cancer Res (2013) 0.86
The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell. Mol Cell Biochem (2013) 0.86
Molecular targeting to treat gastric cancer. World J Gastroenterol (2014) 0.84
Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. Biomacromolecules (2014) 0.84
Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance. Sci Rep (2015) 0.83
Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles. Sci Rep (2016) 0.83
A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging (2011) 0.82
Dual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy. Protein Cell (2014) 0.82
Targeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother (2011) 0.82
Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies. World J Gastroenterol (2013) 0.82
Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharm (2012) 0.82
Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR. Int J Mol Sci (2013) 0.81
HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway. Onco Targets Ther (2016) 0.80
Recent advances in the HER2 targeted therapy of gastric cancer. World J Clin Cases (2015) 0.80
Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med (2015) 0.80
Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis. PLoS One (2015) 0.80
Immunohistochemical Analysis of p53, Ki-67, CD44, HER-2/neu Expression Patterns in Gastric Cancer, and Their Association with One Year Survival in North-West of Iran. Int J Hematol Oncol Stem Cell Res (2013) 0.79
T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis (2014) 0.78
Prognostic values of four Notch receptor mRNA expression in gastric cancer. Sci Rep (2016) 0.78
The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma. Cancer Cell Int (2013) 0.78
Construction and characterization of novel, completely human serine protease therapeutics targeting Her2/neu. Mol Cancer Ther (2013) 0.78
A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulates DR5 in breast cancer cells. Cell Death Dis (2015) 0.78
The role of MAPK signaling pathway in the Her-2-positive meningiomas. Oncol Rep (2016) 0.78
Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer. Nanomedicine (Lond) (2015) 0.77
Efficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation. PLoS One (2014) 0.77
Human epidermal growth factor receptor 2-positive breast cancer: which cytotoxic agent best complements trastuzumab's efficacy in vitro? Onco Targets Ther (2013) 0.77
Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging. Int J Nanomedicine (2012) 0.77
HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report. Mol Clin Oncol (2016) 0.77
Therapeutic advances in women's cancers. Front Biosci (Schol Ed) (2011) 0.76
Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. Pathol Oncol Res (2015) 0.76
The prognostic roles of ALDH1 isoenzymes in gastric cancer. Onco Targets Ther (2016) 0.76
Antibody-based imaging of HER-2: moving into the clinic. Curr Mol Med (2013) 0.76
HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth. Oncotarget (2016) 0.76
Targeted Delivery of 5-fluorouracil with Monoclonal Antibody Modified Bovine Serum Albumin Nanoparticles. Iran J Pharm Res (2015) 0.75
Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anticancer Agents Med Chem (2016) 0.75
Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinformatics (2014) 0.75
Micromixer Based Preparation of Functionalized Liposomes and Targeting Drug Delivery. ACS Med Chem Lett (2016) 0.75
Decoration of pH-sensitive copolymer micelles with tumor-specific peptide for enhanced cellular uptake of doxorubicin. Int J Nanomedicine (2016) 0.75
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells. Int J Nanomedicine (2017) 0.75
Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity. Mol Ther Oncolytics (2015) 0.75
A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int J Mol Sci (2017) 0.75
(99m)Tc-radiolabeled GE11-modified peptide for ovarian tumor targeting. Daru (2017) 0.75
Downregulation of human epidermal growth factor receptor 2 by short hairpin RNA increases chemosensitivity of human ovarian cancer cells. Oncol Lett (2015) 0.75
Suppression of human epidermal growth factor receptor 2 via interference increases the chemosensitivity of ovarian carcinoma. Oncol Lett (2016) 0.75
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer. Int J Mol Sci (2016) 0.75
Current and Emerging Treatment Regimens for HER2-Positive Breast Cancer. P T (2014) 0.75
Multifunctional decoration of alpha-tocopheryl succinate-based NP for cancer treatment: effect of TPP and LTVSPWY peptide. J Mater Sci Mater Med (2017) 0.75
Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein. Biomedicines (2017) 0.75
Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance. Oncotarget (2017) 0.75
Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease. Clin Exp Metastasis (2016) 0.75
Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis. Biosci Rep (2017) 0.75
Neratinib: First Global Approval. Drugs (2017) 0.75
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Role of angiogenesis in tumor growth and metastasis. Semin Oncol (2002) 9.77
Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol (2001) 7.22
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res (2006) 7.18
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res (2004) 6.53
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature (2005) 5.75
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 4.34
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Microvascular permeability. Physiol Rev (1999) 4.12
Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res (2009) 4.02
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 3.87
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell (2004) 3.79
The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci (2008) 3.77
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol (2005) 3.48
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell (2003) 3.20
Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res (2002) 3.14
From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A (1999) 3.00
Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer (1996) 2.95
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene (1995) 2.84
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res (2009) 2.68
Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell (2002) 2.67
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res (2003) 2.61
Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res (2005) 2.59
Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53
The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol (2004) 2.41
Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30
The single transmembrane domains of ErbB receptors self-associate in cell membranes. J Biol Chem (2001) 2.25
Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol (2005) 2.20
Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol (2003) 2.14
High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology (2000) 2.06
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res (2001) 2.06
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res (1995) 2.05
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
The basic biology of HER2. Ann Oncol (2001) 1.97
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol (2001) 1.96
Trastuzumab: triumphs and tribulations. Oncogene (2007) 1.94
Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res (1991) 1.92
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene (1994) 1.88
A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A (2002) 1.86
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer (2003) 1.74
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J (1998) 1.71
Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol (1988) 1.67
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res (2007) 1.67
The epidermal growth factor receptor family. Endocr Relat Cancer (2005) 1.55
Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2009) 1.53
Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer (2007) 1.51
CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther (2005) 1.51
Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer (1993) 1.50
Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res (2003) 1.49
Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res (2007) 1.40
Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel (2004) 1.33
Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst (1993) 1.32
Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer (2008) 1.32
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene (1996) 1.30
The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate (2004) 1.29
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem (2003) 1.27
The role of overexpressed HER2 in transformation. Ann Oncol (2001) 1.27
Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol (2000) 1.26
E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs. Cancer Res (2005) 1.26
Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat (2001) 1.24
An attractive force in metastasis. Nature (2001) 1.24
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res (2005) 1.24
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res (2008) 1.23
Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res (2006) 1.21
Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J (2002) 1.19
Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol (2008) 1.19
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer (2004) 1.17
ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem (2002) 1.17
Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst (1986) 1.17
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res (2005) 1.17
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif (2007) 1.15
Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol (2009) 1.14
Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm (2006) 1.11
Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep (2002) 1.10
A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha down-regulation in breast cancer cells: the role of nuclear factor-kappaB. Mol Endocrinol (2004) 1.10
Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res (2004) 1.09
Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery. Gene Ther (2006) 1.08
Overexpression of HER-2 in ovarian carcinomas. Cancer Res (2001) 1.06
HER2-positive breast cancer: current and future treatment strategies. Drugs (2007) 1.06
HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem (2008) 1.03
Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. J Exp Clin Cancer Res (2013) 1.82
Mesenchymal stem cell-conditioned medium reduces liver injury and enhances regeneration in reduced-size rat liver transplantation. J Surg Res (2013) 1.62
O-acetylation of Arabidopsis hemicellulose xyloglucan requires AXY4 or AXY4L, proteins with a TBL and DUF231 domain. Plant Cell (2011) 1.31
Xylan O-acetylation impacts xylem development and enzymatic recalcitrance as indicated by the Arabidopsis mutant tbl29. Mol Plant (2013) 1.24
XAX1 from glycosyltransferase family 61 mediates xylosyltransfer to rice xylan. Proc Natl Acad Sci U S A (2012) 1.09
Blocking IKKα expression inhibits prostate cancer invasiveness. Pharm Res (2010) 1.07
Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res (2010) 1.05
Deep sequencing of voodoo lily (Amorphophallus konjac): an approach to identify relevant genes involved in the synthesis of the hemicellulose glucomannan. Planta (2011) 1.04
Vascular endothelial growth factor gene delivery for revascularization in transplanted human islets. Pharm Res (2004) 1.01
Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev (2011) 1.00
Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opin Drug Deliv (2005) 0.97
Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Mol Pharm (2010) 0.96
Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm (2011) 0.92
Identification of a LNCaP-specific binding peptide using phage display. Pharm Res (2011) 0.91
Targeted delivery of a triplex-forming oligonucleotide to hepatic stellate cells. Biochemistry (2005) 0.91
The identification of two arabinosyltransferases from tomato reveals functional equivalency of xyloglucan side chain substituents. Plant Physiol (2013) 0.89
Reduced Wall Acetylation proteins play vital and distinct roles in cell wall O-acetylation in Arabidopsis. Plant Physiol (2013) 0.87
Receptor-mediated hepatic uptake of M6P-BSA-conjugated triplex-forming oligonucleotides in rats. Bioconjug Chem (2006) 0.86
Coexpression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function. Mol Pharm (2007) 0.86
Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjug Chem (2007) 0.84
Adenosquamous carcinoma of the pancreas: multidetector-row computed tomographic manifestations and tumor characteristics. J Comput Assist Tomogr (2013) 0.84
Modification in the technique of ear framework fabrication for congenital microtia. J Craniofac Surg (2012) 0.83
Peptides used in the delivery of small noncoding RNA. Mol Pharm (2014) 0.83
PCBP2 siRNA reverses the alcohol-induced pro-fibrogenic effects in hepatic stellate cells. Pharm Res (2011) 0.82
Expression profile and functional activity of peptide transporters in prostate cancer cells. Mol Pharm (2012) 0.82
Highly active platinum nanoparticles on graphene nanosheets with a significant improvement in stability and CO tolerance. Langmuir (2012) 0.81
Classification of Streptomyces phylogroup pratensis (Doroghazi and Buckley, 2010) based on genetic and phenotypic evidence, and proposal of Streptomyces pratensis sp. nov. Syst Appl Microbiol (2013) 0.80
Development of cholesteryl peptide micelles for siRNA delivery. J Control Release (2013) 0.80
Development of streptavidin-based nanocomplex for siRNA delivery. Mol Pharm (2013) 0.79
siRNA delivery and targeting. Mol Pharm (2009) 0.79
A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharm Res (2013) 0.78
Aqueous-ammonia delignification of miscanthus followed by enzymatic hydrolysis to sugars. Bioresour Technol (2012) 0.77
Biological and therapeutic applications of small RNAs. Pharm Res (2011) 0.77
[The diagnostic utility of the Macao predictive values of impulse oscillometry for chronic obstructive pulmonary disease in patients over 45 years old]. Zhonghua Jie He He Hu Xi Za Zhi (2016) 0.77
[Cloning, characterization and application of the promoter region of the alkaline protease gene in Bacillus alcalophillus PB92]. Yi Chuan (2008) 0.77
Targeted nanodiamonds as phenotype-specific photoacoustic contrast agents for breast cancer. Nanomedicine (Lond) (2015) 0.77
Complete genome sequence of a porcine circovirus 2 strain isolated in central china. Genome Announc (2014) 0.75
Transition metal/nitrogen dual-doped mesoporous graphene-like carbon nanosheets for the oxygen reduction and evolution reactions. Nanoscale (2016) 0.75
Diethyl (6-amino-9H-purin-9-yl) methylphosphonate induces apoptosis and cell cycle arrest in hepatocellular carcinoma BEL-7402 cells: Role of reactive oxygen species. Free Radic Res (2010) 0.75
Crystalline metallic Au nanoparticle-loaded α-Bi2O3 microrods for improved photocatalysis. Phys Chem Chem Phys (2012) 0.75
Space-bound optical source for satellite-ground decoy-state quantum key distribution. Opt Express (2014) 0.75
A comparative study on carbon footprint of rice production between household and aggregated farms from Jiangxi, China. Environ Monit Assess (2015) 0.75